|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2002-8-21
|
|
pubmed:abstractText |
Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (Aranesp(TM)) is an erythropoiesis-stimulating glycoprotein that has been shown, in dose-finding studies, to be safe and clinically active when administered to patients with cancer every 1, 2, or 3 weeks. This phase III study compared the safety and efficacy of darbepoetin alfa with placebo in patients with lung cancer receiving chemotherapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
pubmed-author:Aranesp 980297 Study Group,
pubmed-author:BarataFernandoF,
pubmed-author:ColowickAlan BAB,
pubmed-author:FieglMichaelM,
pubmed-author:FontAlbertA,
pubmed-author:GateleyJenniJ,
pubmed-author:MassutiBartomeuB,
pubmed-author:MusilJaromirJ,
pubmed-author:PirkerRobertR,
pubmed-author:SienaSalvatoreS,
pubmed-author:TomitaDianneD,
pubmed-author:VansteenkisteJohanJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
21
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1211-20
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12189224-Adult,
pubmed-meshheading:12189224-Aged,
pubmed-meshheading:12189224-Aged, 80 and over,
pubmed-meshheading:12189224-Anemia,
pubmed-meshheading:12189224-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12189224-Disease Progression,
pubmed-meshheading:12189224-Double-Blind Method,
pubmed-meshheading:12189224-Erythrocyte Transfusion,
pubmed-meshheading:12189224-Erythropoiesis,
pubmed-meshheading:12189224-Erythropoietin,
pubmed-meshheading:12189224-Fatigue,
pubmed-meshheading:12189224-Female,
pubmed-meshheading:12189224-Humans,
pubmed-meshheading:12189224-Length of Stay,
pubmed-meshheading:12189224-Lung Neoplasms,
pubmed-meshheading:12189224-Male,
pubmed-meshheading:12189224-Middle Aged,
pubmed-meshheading:12189224-Patient Admission,
pubmed-meshheading:12189224-Platinum Compounds,
pubmed-meshheading:12189224-Questionnaires,
pubmed-meshheading:12189224-Survival Analysis,
pubmed-meshheading:12189224-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
|
|
pubmed:affiliation |
Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium. johan.vansteenkiste@uz.kuleuven.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
